Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature

  title={Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature},
  author={Ken Hiu-Kan Ip and K J McKerrow},
  journal={Australasian Journal of Dermatology},
  • K. Ip, K. McKerrow
  • Published 23 June 2021
  • Medicine
  • Australasian Journal of Dermatology
Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its… 
Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma
  • Neha Gupta, E. Ruiz
  • Medicine
    Drug Design, Development and Therapy
  • 2022
Treatment of locally advanced basal cell carcinomas requires a multi-disciplinary approach where different modalities including surgery, radiation therapy, Hedgehog Pathway Inhibitors, and immunotherapy can be considered.
DDDT_A_325852 183..190
Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Jamaica Plain, MA, USA Abstract: Basal cell carcinoma (BCC) is the most common cancer in Caucasians, and its incidence


Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
These results provide the basis for larger trials of longer duration to measure the clinical efficacy of itraconazole, especially relative to other HH pathway inhibitors.
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Targeting the HH pathway with sequential arsenic trioxide and itraconazole treatment is a feasible treatment for metastatic BCC, and although some patients experienced stable disease for 3 months, none had tumor shrinkage, which may be owing to transient GLI1 suppression with sequential dosing.
Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib
A case of infiltrative BCC with multiple recurrences is presented, where the patient was treated with vismodegib which led to a complete response and the patient's symptoms due to the locally diffused cancer resolved.
Triple Hedgehog Pathway Inhibition for Basal Cell Carcinoma.
The authors report the successful treatment of a patient with advanced basal cell carcinoma using the combination of vismodegib, itraconazole, and imiquimod, each of which inhibits a different part of the hedgehog pathway.
Synergistic effect of ibuprofen with itraconazole and fluconazole against Cryptococcus neoformans
The results suggest that ibuprofen presents clinical potential when combined with azole drugs in the treatment of cryptococcosis, and no synergistic effects were seen when amphotericin B was combined with ib uprofen.
How to break resistance to HHI (hedgehog inhibitors) in advanced BCC?
  • Br. J. Dermatol.
  • 2020